NBTXR3 Activated by Radiotherapy in Combination With Nivolumab or Pembrolizumab in Patients With Advanced Cancers: A Phase I Trial
Colette J. Shen(Johns Hopkins University), Tanguy Y. Seiwert(Georgetown University), Jiaxin Niu(Western Regional Medical Center), Ari J. Rosenberg, K. Jameson, J.J. Caudell(Moffitt Cancer Center), J. Weiß(UNC Lineberger Comprehensive Cancer Center), Patricia Said(Nanobiotix (France)), Jessica M. Frakes(Moffitt Cancer Center)
International Journal of Radiation Oncology*Biology*Physics
October 25, 2021
Cited by 1
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|652
Albumin-bound paclitaxel in solid tumors: clinical development and future directions
|Drug Design Development and Therapy|2015|253
Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline
|Journal of Clinical Oncology|2020|221